You are here

  • Home
  • Archive
  • Volume 4, Issue Suppl 1
  • 90 Safety, efficacy and transcriptional changes following repeated administration of dapirolizumab pegol in patients with systemic lupus erythematosus: results from a phase i study

Article metrics

Article menu

Download PDFPDF

Poster Session
New therapies and therapeutic targets – SLE
90 Safety, efficacy and transcriptional changes following repeated administration of dapirolizumab pegol in patients with systemic lupus erythematosus: results from a phase i study
Free

 

Online download statistics by month:

Online download statistics by month: March 2017 to March 2024

AbstractFullPdf
Mar 2017403
Apr 20172008
May 201736013
Jun 20174308
Jul 201766012
Aug 201764015
Sep 20177409
Oct 201782021
Nov 20179409
Dec 201760013
Jan 20188404
Feb 20189204
Mar 201813008
Apr 20186406
May 20186006
Jun 20185805
Jul 20182201
Aug 20185805
Sep 20184201
Oct 20187203
Nov 20189008
Dec 201811603
Jan 20199803
Feb 20199504
Mar 20193104
Apr 20191803
May 2019507
Jun 2019202
Jul 2019807
Aug 2019503
Sep 20191202
Oct 20191502
Nov 2019601
Dec 20191102
Jan 2020501
Feb 2020603
Mar 2020104
Apr 2020303
May 2020203
Jun 2020203
Jul 20201002
Aug 2020301
Sep 20201205
Oct 20201605
Nov 20201103
Dec 20201000
Jan 2021602
Feb 2021404
Mar 20211003
Apr 2021201
May 2021103
Jun 2021101
Jul 2021106
Aug 2021205
Sep 2021306
Oct 20216020
Nov 20213010
Dec 20211303
Jan 2022702
Feb 2022902
Mar 20221101
Apr 2022601
May 20221006
Jun 20223204
Jul 20221701
Aug 20221303
Sep 202213010
Oct 2022505
Nov 2022605
Dec 20221200
Jan 20231405
Feb 2023502
Mar 20231000
Apr 20231407
May 2023904
Jun 20231205
Jul 20231205
Aug 2023004
Sep 2023301
Oct 20231103
Nov 20231405
Dec 2023602
Jan 20242102
Feb 2024403
Mar 20246047
Total21520437